Trial Profile
A Phase 2 Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 17 Nov 2021 Status changed from active, no longer recruiting to completed.
- 20 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2020 Planned End Date changed from 1 Nov 2020 to 1 Nov 2021.